Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) swung to net losses attributable to the owners valued at AED 44.10 million in the first half (H1) of 2023, versus profits of AED 6.30 million in H1-22.
The revenues from contracts with customers amounted to AED 859.40 million in H1-23, an annual rise from AED 838.50 million, according to the interim consolidated financial statements.
Basic loss per share attributable to the shareholders hit AED 3.80 during the first six months (6M) of 2023, compared to earnings per share (EPS) worth AED 0.60 in the year-ago period.
Income Statements for Q2-23
In the second quarter (Q2) of 2023, Julphar also shifted to net losses attributable to the equityholders worth AED 41.20 million, against net profits valued at AED 4.70 million a year earlier.
Revenues dropped to AED 405.30 million in Q2-23 from AED 419.90 million in Q2-22. Meanwhile, the loss per share reached AED 3.50, versus a profit per share of AED 0.40.
Accumulated Losses
As of 30 June 2023, the accumulated losses reached AED 295.40 million, equivalent to 25.60% of the ADX-listed company’s capital.
During January-March 2023, the UAE-based firm turned to net losses attributable to the owners totalling AED 2.90 million, versus net profits valued at AED 1.50 million in Q1-22.
